Jefferies Comments on Pfizer's JAK Inhibitor

Jefferies is providing some comments on Pfizer's PFE JAK inhibitor, tofacitinib. “Oral targeted disease modifying Rheumatoid Arthritis (RA) treatments were the hot topic at this year's European League Against Rheumatism (EULAR) annual meeting, last week (May 25-28),” Jefferies writes. “Pfizer's JAK inhibitor tofacitinib is the closest to market. Further clarity and reassurance of the drug's safety was gained from the data presented at the meeting. We expect peak sales of $6.5bn for tofacitinib.” Pfizer closed Friday at $20.93.